Anneliese Schneider
- Oncology top 10%
- CAR-T cell therapy research 5
- Peptidase Inhibition and Analysis 3
- Cancer Cells and Metastasis 2
- Immunology top 10%
- Immunotherapy and Immune Responses 3
- Biosimilars and Bioanalytical Methods 2
- Pharmacology top 5%
- Pharmacogenetics and Drug Metabolism 2
-
- Viral Infectious Diseases and Gene Expression in Insects 2
-
- Monoclonal and Polyclonal Antibodies Research 6
- Co-authors
- Frank JaschinskiKarl‐Hermann SchlingensiepenPatricia DillHans‐Jörg BühringWolfram BruggerFrank GrünebachLothar KanzPeter Brossart
- Cited by
- OncologyImmunologyCancer Research
- Journals
- Journal of Clinical Oncology (1 paper)Cancer Research (1 paper)Journal of Medicinal Chemistry (1 paper)
- Partner nations
- SwitzerlandGermanyNetherlands
In The Last Decade
Anneliese Schneider
18 papers receiving 789 citations
Peers
Comparison fields: 5 of 78
- Oncology 315
- Immunology 220
- Cancer Research 152
- Pharmacology 80
- Molecular Biology 412
Countries citing papers authored by Anneliese Schneider
This map shows the geographic impact of Anneliese Schneider's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anneliese Schneider with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anneliese Schneider more than expected).
Fields of papers citing papers by Anneliese Schneider
This network shows the impact of papers produced by Anneliese Schneider. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anneliese Schneider. The network helps show where Anneliese Schneider may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Anneliese Schneider, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2025 | 1 | |
| 3 | 2024 | 0 | |
| 4 | 2023 | 43 | |
| 5 | 2022 | 20 | |
| 6 | 2022 | 19 | |
| 7 | 2021 | 27 | |
| 8 | 2020 | 5 | |
| 9 | 2014 | 42 | |
| 10 | 2013 | 3 | |
| 11 | 2012 | 1 | |
| 12 | 2012 | 48 | |
| 13 | 2011 | 110 | |
| 14 | 2011 | 84 | |
| 15 | 2007 | 48 | |
| 16 | 2006 | 21 | |
| 17 | The epithelial tumor antigen MUC1 is expressed in hematological malignancies and is recognized by MUC1-specific cytotoxic T-lymphocytes. | 2001 | 171 |
| 18 | 1998 | 109 | |
| 19 | 1996 | 44 | |
| 20 | 1995 | 6 |
About Anneliese Schneider
Anneliese Schneider is a scholar working on Transplantation, Oncology and Immunology, having authored 20 papers that have together received 802 indexed citations. Recurring topics across this work include Monoclonal and Polyclonal Antibodies Research (6 papers), CAR-T cell therapy research (5 papers), Peptidase Inhibition and Analysis (3 papers), Immunotherapy and Immune Responses (3 papers), Viral Infectious Diseases and Gene Expression in Insects (2 papers), Pharmacogenetics and Drug Metabolism (2 papers), Cancer Cells and Metastasis (2 papers) and Biosimilars and Bioanalytical Methods (2 papers). The work is most often cited by research in Oncology (315 citations), Immunology (220 citations) and Cancer Research (152 citations). Anneliese Schneider has collaborated with scholars based in Switzerland, Germany and Netherlands. Frequent co-authors include Frank Jaschinski, Karl‐Hermann Schlingensiepen, Patricia Dill, Hans‐Jörg Bühring, Wolfram Brugger, Frank Grünebach, Lothar Kanz, Peter Brossart, Stefan Wirths and Helmut Greim. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research and Journal of Medicinal Chemistry.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.